Score Breakdown
Below average.
Mineralys is a binary PDUFA play with a well-funded balance sheet ($657M cash) and a clinically validated asset in lorundrostat targeting the large uncontrolled/resistant hypertension market (~20M US patients). The strong Phase 3 data (NEJM/JAMA published), FDA NDA acceptance, and 95% physician intent-to-prescribe are genuine positives. However, the stock faces meaningful headwinds: AstraZeneca's baxdrostat will likely launch first with Big Pharma commercial muscle, 22% short interest reflects legitimate skepticism, 63% annual dilution is extraordinary even for biotech, and coordinated insider selling ahead of PDUFA is a governance red flag. The $1.7B market cap implies significant probability of approval AND commercial success, which seems roughly fairly priced given the binary risk. At current levels, the risk/reward is balanced — not a screaming buy nor a clear short.
Negative cash flow. Can't value it.
Some yellow flags.
Shares melting fast.
No data.
Plenty of cash.
Heavy bearish bets.
Decent.
🐻 Why Bears Hate It
Bears point to the mixed Phase 2 Explore-OSA trial results (March 2026), where lorundrostat failed to meet its primary endpoint of reducing Sleep Apnea (AHI) severity. Significant insider selling has also fueled the short thesis; in the first quarter of 2026, the CEO and CFO sold approximately $14.4 million in stock combined. Furthermore, the company faces a 'second-mover' disadvantage, as AstraZeneca’s rival drug baxdrostat is projected to enter the market approximately two quarters ahead of lorundrostat (Source: Stock Titan, Investing.com, Quiver Quantitative).
🔍 What's In The SEC Filings
The company is flush with cash but is aggressively diluting shareholders while leadership sets up exit ramps ahead of the 2026 PDUFA date.
Massive share count inflation through serial equity offerings.
“81,536,557 and 49,821,915 shares issued and outstanding as of December 31, 2025 and 2024, respectively”
The company increased its outstanding share count by over 63% in a single fiscal year through two major public offerings and an ATM agreement, significantly devaluing existing equity holders.
Coordinated insider exit via newly adopted 10b5-1 trading plans.
“Jon Congleton, Chief Executive Officer and Director Adoption December 30, 2025... up to 300,000 shares”
Four key insiders, including the CEO and CMO, adopted selling plans in Q4 2025 immediately following an NDA submission, indicating a lack of intent to hold through the high-risk PDUFA decision period in late 2026.
High R&D burn with a shift toward administrative bloat.
“General and administrative [38,595, 23,822]”
G&A expenses spiked 62% year-over-year while R&D expenses actually decreased, suggesting a transition from lean drug development to high-cost corporate overhead.
Total reliance on a single, unproven clinical asset with heavy milestone obligations.
“The Company has remaining obligations to pay Tanabe commercial milestone payments of up to $155.0 million”
MLYS has zero revenue and its entire valuation rests on lorundrostat; even if successful, substantial cash outflows to Tanabe will heavily tax early-stage commercialization cash flows.
Intrinsic value should be heavily discounted for the $300M in remaining ATM authorization and the selling pressure expected from insiders starting in early 2026.
The use of 'Emerging Growth Company' exemptions allows the company to avoid auditor attestation of internal controls (SOX 404(b)), masking potential weaknesses in financial reporting during a high-growth phase.